Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab

University Medical Center Groningen (UMCG)

Status: Completed

Conditions: Melanoma

Treatments: Drug: Pemprolizumab

Study type: Observational

Funder types: Other

Identifiers

NCT02600169

20150907

Details and patient eligibility

About

This study is a retrospective cohort study. A database will be created from the data available of all patients that have participate in the named patient program for pembrolizumab in the Netherlands. This database will be used for analysis of response markers and for an evaluation of adverse events.

Full description

This study is a retrospective cohort study. A database will be created from the data available of all patients that have participate in the named patient program for pembrolizumab in the Netherlands. This database will be used for analysis of response markers and for an evaluation of adverse events.

Enrollment: 150 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

All patients that were eligible for treatment with pembrolizumab in the Named Patient Program in the Netherlands.

Trial design

150 participants in 1 patient group

Patients treated with pemprolizumab

Description:

All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma. Patients will be included from all 14 WIN-O (Werkgroep Immunologie Nederland voor Oncologie) centers in the Netherlands. Patients are at least 18 years of age.

Treatment:

Drug: Pemprolizumab